Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending January 26, 2020 Adding lymphopenia component ‘improves’ FLIPI, Blood test may advance diagnosis of GI cancers, T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study, New nomogram better predicts bladder cancer risk, Three or more nonadvanced adenomas no longer spell increased CRC risk, More must reads Must reads for theWeek ending January 19, 2020 ‘Simple’ model predicts severe neutropenia risk in lung cancer patients, Decreased incidence, survival in low-grade serous ovarian cancer illustrate ‘diagnostic shift’, Are providers asking about menstrual bleeding before/during anticoagulant therapy?, UKALL14: Rituximab improves EFS in B-ALL, but four doses not enough, Turoctocog alfa prevented, treated bleeds in previously untreated pediatric patients with severe hemophilia A, More must readsMust reads for theWeek ending January 12, 2020 New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors, Insurance coverage mediates racial disparities in breast cancer, Eradicating H. pylori may cut risk of gastric cancer, Navitoclax may overcome ruxolitinib resistance in MF, Unique T cell populations pinpointed in hepatocellular carcinoma tissue, More must readsMust reads for theWeek ending January 5, 2020 Pelvic insufficiency fractures are common after chemoradiotherapy for cervical cancer, Ibrutinib Plus R-CHOP Warrants Investigation for Some DLBCL Subgroups, MATRIX-RICE Plus Transplant Looks Effective in Poor Prognosis DLBCL Group, Adding Lenalidomide to R-MiniCHOP Did Not Improve Survival, Promising Frontline Option for Immunosuppression Associated Lymphomas, More must readsMust reads for theWeek ending January 5, 2020 Pelvic insufficiency fractures are common after chemoradiotherapy for cervical cancer, Ibrutinib Plus R-CHOP Warrants Investigation for Some DLBCL Subgroups, MATRIX-RICE Plus Transplant Looks Effective in Poor Prognosis DLBCL Group, Adding Lenalidomide to R-MiniCHOP Did Not Improve Survival, Promising Frontline Option for Immunosuppression Associated Lymphomas, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 last »
